Freedom from disease activity in multiple sclerosis
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
20421571
DOI
10.1212/wnl.0b013e3181dbb51c
PII: 74/17_Supplement_3/S3
Knihovny.cz E-resources
- MeSH
- Antirheumatic Agents therapeutic use MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Immunologic Factors therapeutic use MeSH
- Remission Induction MeSH
- Humans MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Natalizumab MeSH
- Multiple Sclerosis, Relapsing-Remitting drug therapy MeSH
- Arthritis, Rheumatoid drug therapy physiopathology MeSH
- Multiple Sclerosis drug therapy physiopathology MeSH
- Severity of Illness Index MeSH
- Expert Testimony MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antirheumatic Agents MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Immunologic Factors MeSH
- Antibodies, Monoclonal MeSH
- Natalizumab MeSH
BACKGROUND: Multiple sclerosis (MS) shares many pathologic features with other immune-mediated inflammatory diseases, such as rheumatoid arthritis, Crohn disease, and psoriasis. The development of effective biologic agents for rheumatoid arthritis has resulted in a treatment paradigm shift such that disease remission is now an explicit goal. EXPERT CLINICAL OPINION: The traditional immunomodulatory disease-modifying therapies for MS (interferon beta and glatiramer acetate) delay disease progression and reduce activity on brain MRI to varying degrees; however, they have not been demonstrated to induce disease remission. Therefore, the concept of disease remission or freedom from disease activity in MS has received little attention from the neurology community. We discuss some potential definitions of disease remission in MS and whether freedom from disease activity can become an increasingly useful measure of therapeutic response. FUTURE DIRECTIONS: Future research should be directed at determining the long-term significance of freedom from disease activity during a short-term clinical trial in relapsing-remitting MS.
References provided by Crossref.org
